Cerebral small vessel disease (cSVD) is a highly prevalent and prognostically relevant condition in older adults, yet it is not specifically addressed in current dyslipidaemia management guidelines. Emerging data support its role as a potential modifier of residual vascular risk, suggesting that recognizing cSVD could guide a more intensive LDL-C lowering strategy to improve both cardiovascular and cerebrovascular outcomes.
